The UC Davis Cancer Center is a matrix organization under the aegis of the UC Davis Health System integrating the UC Davis School of Medicine and the UC Davis Medical Center, and the University of California, Davis. Located on the campus of the UC Davis Medical Center in Sacramento, California, its administrative clinical and research facilities are under the leadership of the Director and Principal Investigator of this P30 application. The Cancer Center draws its 209 members from the faculty of UC Davis and investigators at the Lawrence Livermore National Laboratory (LLNL), the USDA Western Human Nutrition Research Center and the California Department of Public Health. Peer-reviewed funding for UC Davis totals $30, 997, 409 of which $6,615,009 is provided by the NCI. Peer-reviewed funded research projects of the LLNL members totals $9, 467, 454, of which $2,499,000 is provided by the NCI. Investigations at the other organizations contributing members are provided research funding through the US Department of Agriculture and the State of California respectively. At the UC Davis Cancer Center, research is organized into si programs: (1) Molecular Oncology, (2) Cancer Biology in Animals, (3) Cancer Therapeutics, (4) Cancer Etiology, Prevention, and Control, (5) Prostate Cancer, and (6) Biomedical Technology. This first time, competitive application for a P30 [Cancer Center Support Grant] proposes support for (1) senior leadership, (2) program leadership, (3) developmental programs, (4) administration, (5) planning and evaluation activities, (6) shared resources including molecular pathology, optical pathology, optical biology, mouse biology, the clinical trials support unit, biostatistics/bioinformatics, and pharmacokinetics, (7) the Protocol Review and Monitoring System, and (8) protocol-specific research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA093373-01
Application #
6416140
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
2002-07-01
Project End
2005-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
1
Fiscal Year
2002
Total Cost
$1,260,795
Indirect Cost
Name
University of California Davis
Department
Urology
Type
Schools of Medicine
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Riess, Jonathan W; Gandara, David R; Frampton, Garrett M et al. (2018) Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol 13:1560-1568
Withers, Sita S; Moore, Peter F; Chang, Hong et al. (2018) Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs. Dev Comp Immunol 87:64-74
Zhang, Jin; Xu, Enshun; Ren, Cong et al. (2018) Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant p53 by Downregulating PTEN. Cancer Res 78:1511-1521
Rowson-Hodel, A R; Wald, J H; Hatakeyama, J et al. (2018) Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer. Oncogene 37:197-207
Wang, Minan; Yao, Li-Chin; Cheng, Mingshan et al. (2018) Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J 32:1537-1549
York, D; Sproul, C D; Chikere, N et al. (2018) Expression and targeting of transcription factor ATF5 in dog gliomas. Vet Comp Oncol 16:102-107
Fletcher, Kyle; Klosterman, Steven J; Derevnina, Lida et al. (2018) Comparative genomics of downy mildews reveals potential adaptations to biotrophy. BMC Genomics 19:851
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Yuan, Ye; He, Yixuan; Bo, Ruonan et al. (2018) A facile approach to fabricate self-assembled magnetic nanotheranostics for drug delivery and imaging. Nanoscale 10:21634-21639
Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987

Showing the most recent 10 out of 836 publications